LUND, Sweden, Oct. 18, 2022 /PRNewswire/ -- RhoVac AB (publ) announces today, October 18th 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons.
Swedish firm RhoVac has reported that its Phase IIb BRaVac clinical trial of drug candidate, RV001 (onilcamotide), in prostate cancer patients failed to meet the primary endpoint.
STOCKHOLM, Nov. 13, 2020 /PRNewswire/ -- RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of Cancer (JITC). The scientifically reviewed article reports that the treatment with RhoVac's drug candidate RV001 was safe and well tolerated, and that a long-lasting immune response could be generated in the vast majority of patients. In the patients who had a measurable PSA when they started the study, a markedly increased PSA doubling time was seen, indicating cancer-specific effectiveness.